Vistagen advances intellectual property program to expand patent protection for ph94b to include treatment of adjustment disorder

South san francisco, calif.--( business wire )--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that the company has taken important strategic steps to secure additional patent protection for its lead product candidate, ph94b, through the recent filing of national applications at the u.s. patent and trademark office (uspto) and counterpart patent authorities in major pharmaceutical markets outside the u.s. for the treatment of adjustment disorder (ajd).
VTGN Ratings Summary
VTGN Quant Ranking